Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: Influence on antitumor efficacy and systemic clearance

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 5, 2013, Pages 585-592

  Sprowl, J A ^a   Van Doorn, L ^b   Hu, S ^a   Van Gerven, L ^b   De Bruijn, P ^b   Li, L ^a   Gibson, A A ^a   Mathijssen, R H ^b   Sparreboom, A ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISPLATIN; MESSENGER RNA; ORGANIC CATION TRANSPORTER 2;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CIMETIDINE; CISPLATIN; DRUG SYNERGISM; FEMALE; HEAD AND NECK NEOPLASMS; HEK293 CELLS; HUMANS; MALE; MICE; MIDDLE AGED; ORGANIC CATION TRANSPORT PROTEINS; OVARIAN NEOPLASMS;

EID: 84886727293     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.145     Document Type: Article

References (41)

1. Go, R.S. & Adjei, A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 17, 409-422 (1999).
2. Siddik, Z.H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 (2003).
3. de Jongh, F.E. et al. Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer 88, 1199-1206 (2003).
4. Planting, A.S., van der Burg, M.E., de Boer-Dennert, M., Stoter, G. & Verweij, J. Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br. J. Cancer 68, 789-792 (1993).
5. McKeage, M.J. Comparative adverse effect profiles of platinum drugs. Drug Saf. 13, 228-244 (1995).
6. Meyer, K.B. & Madias, N.E. Cisplatin nephrotoxicity. Miner. Electrolyte Metab. 20, 201-213 (1994).
7. Santoso, J.T., Lucci, J.A. 3rd, Coleman, R.L., Schafer, I. & Hannigan, E.V. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial. Cancer Chemother. Pharmacol. 52, 13-18 (2003).
8. Weiner, M.W. & Jacobs, C. Mechanism of cisplatin nephrotoxicity. Fed. Proc. 42, 2974-2978 (1983).
9. Nelson, J.A., Santos, G. & Herbert, B.H. Mechanisms for the renal secretion of cisplatin. Cancer Treat. Rep. 68, 849-853 (1984).
10. Williams, P.D. & Hottendorf, G.H. Effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex. Cancer Treat. Rep. 69, 875-880 (1985).
11. Miura, K., Goldstein, R.S., Pasino, D.A. & Hook, J.B. Cisplatin nephrotoxicity: Role of filtration and tubular transport of cisplatin in isolated perfused kidneys. Toxicology 44, 147-158 (1987).
12. Fujita, T., Urban, T.J., Leabman, M.K., Fujita, K. & Giacomini, K.M. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J. Pharm. Sci. 95, 25-36 (2006).
13. Wright, S.H. & Dantzler, W.H. Molecular and cellular physiology of renal organic cation and anion transport. Physiol. Rev. 84, 987-1049 (2004).
14. Filipski, K.K., Mathijssen, R.H., Mikkelsen, T.S., Schinkel, A.H. & Sparreboom, A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86, 396-402 (2009).
15. Ciarimboli, G. et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 176, 1169-1180 (2010).
16. Zhang, J. & Zhou, W. Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem. Toxicol. 50, 2289-2293 (2012).
17. Zhang, L., Brett, C.M. & Giacomini, K.M. Role of organic cation transporters in drug absorption and elimination. Annu. Rev. Pharmacol. Toxicol. 38, 431-460 (1998).
18. Urakami, Y., Akazawa, M., Saito, H., Okuda, M. & Inui, K. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J. Am. Soc. Nephrol. 13, 1703-1710 (2002).
19. Franke, R.M. et al. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin. Cancer Res. 16, 4198-4206 (2010).
20. Sleijfer, D.T. et al. The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60, 2823-2828 (1987).
21. Schellens, J.H. et al. Relationship between the exposure to cisplatin, DNAadduct formation in leucocytes and tumour response in patients with solid tumours. Br. J. Cancer 73, 1569-1575 (1996).
22. Schellens, J.H. et al. Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer. Anticancer. Drugs 12, 667-675 (2001).
23. Burger, H. et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br. J. Pharmacol. 159, 898-908 (2010).
24. Johnson, P., Gray, D., Mowat, M. & Benchimol, S. Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol. Cell. Biol. 11, 1-11 (1991).
25. Collinet, P. et al. In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice. J. Obstet. Gynaecol. Res. 32, 449-453 (2006).
26. Nies, A.T., Hofmann, U., Resch, C., Schaeffeler, E., Rius, M. & Schwab, M. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS ONE 6, e22163 (2011).
27. Grahnén, A., von Bahr, C., Lindström, B. & Rosén, A. Bioavailability and pharmacokinetics of cimetidine. Eur. J. Clin. Pharmacol. 16, 335-340 (1979).
28. Filipski, K.K., Loos, W.J., Verweij, J. & Sparreboom, A. Interaction of Cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 14, 3875-3880 (2008).
29. Haragsim, L., Zima, T. & Nemecek, K. Nephrotoxic effects of platinum cytostatics-preventative effects of nifedipine and cimetidine. Sb. Lek. 95, 173-183 (1994).
30. Katsuda, H. et al. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol. Pharm. Bull. 33, 1867-1871 (2010).
31. Lancaster, C.S. et al. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol. Cancer Ther. 12, 1537-1544 (2013).
32. Howell, S.B., Safaei, R., Larson, C.A. & Sailor, M.J. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol. Pharmacol. 77, 887-894 (2010).
33. Ivy, K.D. & Kaplan, J.H. A re-evaluation of the role of hCTR1, the human highaffinity copper transporter, in platinum-drug entry into human cells. Mol. Pharmacol. 83, 1237-1246 (2013).
34. Clouse, T., Geisler, J.P., Manahan, K.J., Gudenkauf, T.J., Linnemeier, G. & Wiemann, M.C. Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel? Gynecol. Oncol. 95, 270-271 (2004).
35. Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T. & Inui, K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 319, 879-886 (2006).
36. Matsushima, S. et al. The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab. Dispos. 37, 555-559 (2009).
37. Ohta, K.Y., Inoue, K., Yasujima, T., Ishimaru, M. & Yuasa, H. Functional characteristics of two human MATE transporters: Kinetics of cimetidine transport and profiles of inhibition by various compounds. J. Pharm. Pharm. Sci. 12, 388-396 (2009).
38. Tsuda, M. et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J. Pharmacol. Exp. Ther. 329, 185-191 (2009).
39. Koepsell, H., Lips, K. & Volk, C. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 24, 1227-1251 (2007).
40. Sprowl, J.A. et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc. Natl. Acad. Sci. USA 110, 11199-11204 (2013).
41. de Jongh, F.E., Gallo, J.M., Shen, M., Verweij, J. & Sparreboom, A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother. Pharmacol. 54, 105-112 (2004).